MSA Trust

Other MSA and Neurology Research

Research news from around the world…

 

June 2024: New blood test to detect Parkinson’s Disease being researched

June 2024: Cambridge Biomedical Research Centre videos – Patient and Public Involvement in research

April 2024: Skin biopsy as a potential method towards a test for Parkinson’s

Strain of gut bacteria contributes to the development of Parkinson’s disease

Researchers in Wales are leading the way in the development of new ways of diagnosing Parkinson’s Disease (PD) and Parkinson’s Disease Dementia (PDD)

Eye scans can detect Parkinsons disease

NIHR Be Part of Research Winter 2024 newsletter

Promising early results from Parkinson’s vaccine study | Parkinson’s UK (parkinsons.org.uk)

AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)

NIHR Autumn 2023 Be Part of Research Newsletter available here

TENS Shows Promise for Obstructive Sleep Apnoea Treatment

Practical Neurology Multiple System Atrophy Podcast with Dr Chelban and Dr Yee Yen Goh

A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson’s Disease

Study traces cystitis contribution to neurological disorder MSA. Read the full article here.

Researchers have developed a novel assay that can not only reliably detect α-synuclein aggregates, but also differentiate between neurodegenerative diseases – Sowing the seeds of diagnosis: a novel assay for abnormal α-synuclein detection. The full article is available here

Practical Neurology Journal article ‘Multiple System Atrophy‘ – This is a practical guide to diagnosing and managing multiple system atrophy (MSA). We explain the newly published Movement Disorders Society Consensus Diagnostic Criteria, which include new ‘Clinically Established MSA’ and ‘Possible Prodromal MSA’ categories, hopefully reducing time to diagnosis. We then highlight the key clinical features of MSA to aid diagnosis. We include a list of MSA mimics with suggested methods of differentiation from MSA. Lastly, we discuss practical symptom management in people living with MSA, including balancing side effects, with the ultimate aim of improving quality of life.

Health related quality-of-life and burden for caregivers of individuals with neurogenic orthostatic hypotension

Multiple system atrophy: α-Synuclein strains at the neuron-oligodendrocyte crossroad

Nigral glucose metabolism as a diagnostic marker of neurodegenerative parkinsonian syndromes

Identical structures of α-synuclein filaments from Parkinson’s disease and dementia with Lewy bodies

Woman who can ‘smell Parkinson’s’ helps scientists come up with breakthrough diagnostic test

Journal of Parkinson’s Disease Journal article, ‘Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?’

Researchers from the University of Florida will begin testing a new artificial intelligence tool that can help distinguish a precise diagnosis between Parkinson’s Disease, Multiple System Atrophy Parkinsonian variant (MSA-P), or Progressive Supranuclear Palsy (PSP)

New Study to Evaluate Mesenchymal Stem Cells to Treat MSA in USA

Modag has secured funding to take anle138b into the clinic in MSA

Lundbeck have announced a phase II trial – the AMULET research study – which will be recruiting a small number of people with MSA in the US and Japan

Further information about AMULET trial is available here

PET scan algorithm has potential to diagnose Parkinson’s, MSA and PSP

Alterity to proceed with Phase II trial of MSA therapy after MHRA authorisation

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH) :: Theravance Biopharma

Alterity receives MHRA authorisation for Phase II trial of MSA therapy (clinicaltrialsarena.com)

Spinal implant helps with blood pressure symptoms in MSA

ERN-RND webinar: “New MDS criteria for clinical diagnosis of MSA” – presented recently via webinar and will be published later in 2022

AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference, and Potential In First for the Field, α-Synuclein PET. Only for Multiple System Atrophy | ALZFORUM

Exploring the benefits and barriers to Nordic walking in people with Parkinson’s disease: a feasibility study

The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy

Lundbeck launches a phase II study for potential new treatment of multiple system atrophy

Alpha-synuclein Test May Aid Earlier Diagnosis

Ground-breaking COVID-19 antiviral treatment trial opens to recruitment. See the NIHR announcement here and the trial homepage here

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in New Zeland

*For Researchers* Fund Sophia, managed by the King Baudouin Foundation, has launched a call for research projects on Multiple System Atrophy (MSA) and related diseases characterized by Parkinsonism but excluding idiopathic Parkinson. They are offering € 150.000 to support a research project over a period of 2 years. Deadline for application: 12/01/2022 See here for more information Sophia (Fund) | Koning Boudewijnstichting (kbs-frb.be)

News: Whole genome sequencing helps to unravel mystery of rare disease diagnosis | NIHR

Alterity Therapeutics announce ‘Clinical trial to enroll patients with early-stage Multiple Systems Atrophy’, more information in the announcement here

EmeraMed builds momentum in rare disease. EmeraMed’s emeramide saw its PTSR in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) rise by nine points each after a Phase II trial was completed. The PTSR in PSP currently sits at 27% while that in MSA is now 56%. PSP and MSA are both atypical forms of Parkinson’s disease. The Phase II placebo-controlled crossover study (NCT04184063) evaluating the drug’s effect on symptoms and health-related quality of life over 28 days enrolled 20 patients with PSP or MSA. Emermaide, also known as NBMI, is an oral isophthalamide derivative that can prevent oxidative damage and reduce disease toxicity. The study completion, which was posted to ClinicalTrials.gov on 23 September, resulted in a modest one-point bump to the drug’s LoA in MSA to 2%, but there was no LoA change in PSP, which remained at 1%. EmeraMed is headquartered in Ireland and also operates in the US and Sweden. Read more about the trial on the ClinicalTrials.gov website

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021 (prnewswire.com) See the conference poster here

Results of M-Star trial announced. We have been disappointed to learn from Biohaven that one of the possible treatment drugs, Verdiperstat, for MSA has not given the results hoped for in the phase three trial undertaken over the past year. Our Biohaven colleagues have said ‘Thank you so much for all your incredible effort and hard work on this trial. We could not have done this without your support – from helping with recruitment to connecting us with people with MSA and their families to understand their experience better. We are hoping that this global MSA study (the largest ever conducted) will help further the research for this rare degenerative disease. ‘ Read the full press release here. https://www.prnewswire.com/news-releases/biohaven-provides-update-on-phase-3-trial-and-multiple-system-atrophy-msa-program-301385193.html?tc=eml_cleartime

 

Here is a podcast by Dr Camille Carroll Associate Professor and Honorary Consultant Neurologist Peninsula Medical School (Faculty of Health), NSL for Neurology NIHR CRN, talking about The role of digital, technology, such as sensors and wearables, in clinical trials

Research project ‘Abdominal Binders to Treat Orthostatic Hypotension in Multiple System Atrophy’ receives additional funding

Alterity Therapeutics press release announces publication of data for ATH434 (a small molecule drug candidate) in a mouse model of Multiple System Atrophy

The full publication ‘ATH434 Reduces a-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy’ on the Movement Disorders Journal website

Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy

Researchers move closer to a test that can sniff out Parkinson’s

Creating drugs to restore mitochondria and stop Parkinson’s

Parkinson’s results beyond researchers’ wildest dreams

The MSA Coalition (USA) research news and therapeutic pipeline summary